Mirati 849-01- A Phase 1/2 Multiple Expansion Cohort Trial Of Mrtx849 In Patients With Advanced Solid Tumors With Kras G12c Mutation
Posted Date: Aug 5, 2020
- Investigator: Muhammad Riaz
- Specialties: Cancer, Colorectal Cancer, Lung Cancer, Oncology
- Type of Study: Drug
This is a multi-center, Phase 1/2, multiple expansion cohort trial evaluating the safety, PK, metabolites, PD and clinical activity/efficacy of MRTX849 in patients with advanced solid tumor malignancies with KRAS G12C mutation. The primary endpoints of this study are Overall response rate and progression free survival.
Criteria:
To Be Eligible: Must Have Histologically Confirmed Diagnosis Of A Solid Tumor Malignancy With Kras G12c Mutation, Unresectable Or Metastatic Disease, Life Expectancy Of At Least 3 Months, Ecog 0 Or 1, No Serious Illness, Uncontrolled Inter-Current Illness, Psychiatric Illness, Active Or Uncontrolled Infection, Or Other Medical History That May Interfere With Participation Or Results
Keywords:
Phase 1, Advanced Solid Tumor
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com